Breast Cancer : Targets and Therapy最新文献

{"title":"Continuous Anlotinib Combined with Oral Vinorelbine has Shown Anti-Tumor Efficiency in Refractory HER2 Negative Advanced Breast Cancer.","authors":"Jia-Yi Huang, Yan Zhang, Cai-Wen Du","doi":"10.2147/BCTT.S534082","DOIUrl":"10.2147/BCTT.S534082","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the efficacy and safety of continuous administration of anlotinib combined with oral vinorelbine in refractory human epidermal growth factor-2 (HER2) negative advanced breast cancer (ABC).</p><p><strong>Patients and methods: </strong>This retrospective study included 41 HER2 negative ABC patients who received anlotinib (8mg orally per day without interruption) plus oral vinorelbine during November 2019 and February 2023. These patients have received at least two treatments in the past. The efficacy and adverse events (AEs) of these patients need to be evaluated.</p><p><strong>Results: </strong>The median follow-up time for this study was 35.6 months. Among 41 patients with HER2 negative ABC, 16 were HR positive/HER2 negative and 25 were triple negative breast cancer (TNBC). The median progression free survival (PFS) and overall survival (OS) were 6.7 months (95% CI, 4.9-8.5 months) and 28.3 months (95% CI, 10.6-46.0 months). There were no statistical differences in PFS (p=0.200) and OS (p=0.494) between the HR positive/HER2 negative and TNBC subgroups. The objective response rate (ORR), clinical benefit rate (CBR) and disease control rate (DCR) were 22.0%, 61.0% and 82.9%, respectively. Forty patients (97.6%) experienced varying grades of AEs and 31.7% of patients for grades 3-4. The most common grade 3-4 AEs that we observed were neutropenia (17.1%), leukopenia (9.8%) and diarrhea (9.8%).</p><p><strong>Conclusion: </strong>Continuous administration of anlotinib combined with oral vinorelbine demonstrates to be efficacious and well tolerated for refractory HER2 negative ABC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"545-555"},"PeriodicalIF":3.3,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12219184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Strategies to Reducing Interval Breast Cancers: A Systematic Review.","authors":"Rachel Sze Jen Goh, Bryan Chong, Selvie Yeo, Shao Yun Neo, Qin Xiang Ng, Serene Si Ning Goh","doi":"10.2147/BCTT.S532884","DOIUrl":"10.2147/BCTT.S532884","url":null,"abstract":"<p><strong>Background: </strong>Interval breast cancers (IBCs) are detected between regular mammographic screenings after an initially negative result. Studies have shown that the prognosis of IBCs is similar to that of unscreened symptomatic cancers and is hence a surrogate used to assess the effectiveness of screening programs. This systematic review consolidates the current literature available on strategies to reduce the rates of IBC.</p><p><strong>Methods: </strong>Following PRISMA guidelines, three databases were searched from inception till October 29, 2023 to identify papers, which reported IBC rates. Key search terms included \"interval breast cancer\", \"mammogram\", \"tomosynthesis\" and \"screening\".</p><p><strong>Results: </strong>A total of 32 articles were included. Fourteen studies discussed the use of digital breast tomosynthesis (DBT) as an alternative screening modality to mammograms. Six studies discussed the use of artificial intelligence (AI) on mammograms, five studies discussed the use of supplemental modalities including ultrasonography (US) in addition to mammograms, five studies discussed varying screening intervals and two studies discussed tamoxifen use.</p><p><strong>Conclusion: </strong>The trajectory of IBCs can be altered by early detection when they are more amenable to treatment, through advanced screening techniques, adjusting inter-screening intervals and modifiable risk factors. The goal is to create a screening protocol that is economically effective and accessible to various populations.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"531-544"},"PeriodicalIF":3.3,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond.","authors":"Alex Agelidis, Anna Ter-Zakarian, Mohammed Jaloudi","doi":"10.2147/BCTT.S516125","DOIUrl":"10.2147/BCTT.S516125","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) represents a particularly aggressive and heterogeneous subtype of breast cancer, associated with poor prognosis and limited treatment options. This review delves into the rising incidence of TNBC, particularly among younger women, and explores the significant demographic disparities that contribute to variations in incidence, treatment access and survival outcomes. We provide a discussion of TNBC's molecular and genetic landscape, including key pathways revolving around TP53, BRCA1/2 mutations, and PI3K/AKT signaling, which have informed the development of targeted therapies. Recent practice-changing studies are highlighted, which have resulted in the integration of immune checkpoint inhibitors in both early-stage and metastatic settings, the application of PARP inhibitors for BRCA-mutated TNBC and the introduction of antibody-drug conjugates as valuable new therapeutic options. We also review the role of neoadjuvant chemotherapy, novel biomarkers such as tumor-infiltrating lymphocytes, and advancements in diagnostic tools, including machine learning-based imaging and spatial transcriptomics, which are all driving shifts towards personalized approaches. This review synthesizes emerging research and major changes in clinical practice to provide a concise overview of the recent innovations and upcoming trends in TNBC diagnosis and therapy.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"523-529"},"PeriodicalIF":3.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer.","authors":"Kexin Zhao, Jun Zhang, Zhe Yang, Rong Wang, Yuhuan Shi, Yanan Ji, Shengjun Zhang, Minli Liu","doi":"10.2147/BCTT.S527906","DOIUrl":"10.2147/BCTT.S527906","url":null,"abstract":"<p><p>Breast cancer (BC) is the most common type of cancer among women worldwide. A large number of studies have found that the high expression or dysregulation of cyclin-dependent protein kinases (CDKs) is closely associated with breast cancer. For example, the CDK4/6-Rb axis is involved in the G1/S phase transition of the cell cycle and plays an important role in BC; CDK1 and its associated cyclin are commonly involved in mitotic progression, and increased expression of CDK1-associated cyclin has been observed in BC; loss of CDK12 significantly ameliorates triple-negative breast cancer. CDKs are one of the major families within the group of PROteolysis Targeting Chimeras (PROTACs)-degraded kinases. PROTAC is a potent technology for protein-targeted degradation, whose molecules consist of the ligand of the Protein of Interest (POI), the ligand of the E3 ubiquitin ligase (E3), and a Linker. After binding to POI, PROTAC can recruit E3 to ubiquitinate POI via ubiquitin-proteasome mediated degradation. In this review, we summarize relevant research results and review that PROTAC can effectively inhibit the proliferation of breast cancer cells by inducing ubiquitination of CDK1, CDK4/6, CDK9, CDK12/13 and their subsequent degradation by proteasomes, which is expected to be a novel approach for the treatment of breast cancer.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"511-521"},"PeriodicalIF":3.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-Based Multi-Modal Therapy Combining with Immunotherapy to Develop a Vaccine-Like Effective Treatment for Triple-Negative Breast Cancer.","authors":"Mengyan Dai, Zuhong Tian, Fanyuan Xu, Bang Yao, Hongxia Liang, Dongyan Li, Jiangang Wang, Junyan Rong, Tianshuai Liu, Haili Tang, Hongbing Lu, Wenli Zhang","doi":"10.2147/BCTT.S518625","DOIUrl":"10.2147/BCTT.S518625","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is an aggressive malignancy with high metastasis and recurrence rates. Current treatments like chemotherapy and immunotherapy face challenges due to chemotherapy side effects, limited immunotherapy applicability, and TNBC's immunosuppressive microenvironment.</p><p><strong>Purpose: </strong>To achieve a more effective treatment for TNBC, a novel therapeutic strategy has been developed, which uses X-ray excited photodynamic therapy (X-PDT) to activate the tumor immune microenvironment following with the immunotherapy of Anti-CTLA4.</p><p><strong>Methods: </strong>Base on the 4T1 tumor mouse model, this study initially investigated the regulatory effects of X-PDT on the tumor immune microenvironment. Subsequently, the therapeutic efficacy of combining X-PDT with Anti-CTLA4 was evaluated for its inhibitory effects on primary, metastatic, and recurrent tumors. The underlying mechanisms were further elucidated through comprehensive techniques including flow cytometry, ELISA, and immunofluorescence assays.</p><p><strong>Results: </strong>The synergistic strategy can effectively ablate the primary tumor while inhibiting metastasis and preventing recurrence like a vaccine. It enhances intratumoural dendritic cells (DCs) maturation (from 25.7% to 58.3%, <i>P</i> < 0.05) and immune T cell infiltration activating a strong anti-tumor immune response. The anti-tumor efficacy of synergistic therapy is enhanced by 2.5 times comparing with immunotherapy alone, while the tumor metastasis has been inhibited significantly. The maturation level of mature dendritic cells was increased from 26.7% to 86.3% (<i>P</i> < 0.01). The intratumoural CD8⁺/CD4⁺ T cells were increased from 0.51% and 1.54% to 15.4% and 23.1% (<i>P</i> < 0.0001), respectively. The synergistic therapy exerts a powerful vaccine-like long-term immune memory function to prevent tumor recurrence with the elevated level of effector memory T (Tem) cells (from 12.8% to 33.3%, <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Based on the 4T1 mouse model, developed an effective vaccine-like therapeutic strategy combining X-PDT with Anti-CTLA4, which can effectively ablate tumors, inhibit metastasis, and prevent tumor recurrence. This work may provide a novel effective therapeutic modality for the clinical treatment of TNBC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"483-496"},"PeriodicalIF":3.3,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prognostic Nutritional Index-Based Nomogram to Predict Breast Cancer Metastasis: A Retrospective Cohort Validation.","authors":"Zhimin Chen, Honglan Gao, Mingwen Cheng, Chenglin Song","doi":"10.2147/BCTT.S523001","DOIUrl":"10.2147/BCTT.S523001","url":null,"abstract":"<p><strong>Background: </strong>The prognostic nutritional index (PNI) is significantly associated with the prognosis of breast cancer (BC). However, the relationship between PNI and BC metastasis has not yet been thoroughly studied. This study aims to explore the role of PNI in BC metastasis and develop a predictive nomogram model.</p><p><strong>Methods: </strong>A retrospective cohort of 311 BC patients was analyzed. The restricted cubic spline (RCS) was utilized to explore the nonlinear relationships between PNI, geriatric nutritional risk index (GNRI), neutrophil percentage-to-albumin ratio (NPAR), hemoglobin, albumin, lymphocyte, and platelet (HALP) ratio and BC metastasis. Multivariate logistic regression analysis was conducted to identify the influencing factors of BC metastasis. A nomogram model was established and internally validated. The performance and clinical applicability of the model were assessed through the area under the receiver operating characteristic (ROC) curve (AUC), calibration curve, Hosmer-Lemeshow test, and decision curve analysis (DCA).</p><p><strong>Results: </strong>RCS analysis demonstrated nonlinear associations between PNI and HALP with BC metastasis (P for nonlinear < 0.05). PNI and other factors such as T and N stage etc. were identified as independent influencing factors for BC metastasis. The nomogram based on these factors demonstrated strong predictive ability, with the AUCs of 0.85 (95% confidence interval [CI] 0.79, 0.91) and 0.82 (95% CI 0.71, 0.93) in the training and validation set, respectively. The calibration curve, Hosmer-Lemeshow test, and DCA further confirmed its clinical utility.</p><p><strong>Conclusion: </strong>PNI is an independent predictor of BC metastasis. This PNI-based nomogram provides a practical and user-friendly tool for assessing BC metastasis risk.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"497-510"},"PeriodicalIF":3.3,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ALKBH5 Promotes Breast Cancer Stemness Through Regulating Wnt/β-Catenin Signaling.","authors":"Kailin Wang, Kaiting Wang","doi":"10.2147/BCTT.S520532","DOIUrl":"10.2147/BCTT.S520532","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most prevalent disease and the fourth cause of cancer death among female globally. The N6-methyladenylate methylation (m⁶A) demethylase alpha-ketoglutarate-dependent dioxygenase alkB homolog 5 (ALKBH5) decreases modification of RNA, while its role in regulating breast cancer development remains unclear.</p><p><strong>Methods: </strong>ALKBH5-silenced breast cancer cell-line MCF-7 was constructed to investigate its functional impact. Cell proliferation, migration and invasion ability were evaluated by CCK8 and transwell assays under ALKBH5 inhibition. Spheroid formation and in vitro extreme limiting dilution analysis (ELDA) were performed to elucidate the effect of ALKBH5 deficiency on stemness of MCF-7 cells. The m⁶A modification level of <i>CTNNB1</i> and the interaction of ALKBH5 and <i>CTNNB1</i> were investigated by Methylated RNA immunoprecipitation (MeRIP) and RIP assay respectively.</p><p><strong>Results: </strong>Silencing ALKBH5 significantly suppressed MCF-7 cell proliferation, migration, and invasion abilities. Moreover, ALKBH5 depletion also diminished the stemness of breast cancer cells in vitro. Further investigation illustrated that ALKBH5 may regulate Wnt/β-catenin signaling via an m⁶A-dependant manner. Clinical data analysis demonstrated a strong positive relationship between ALKBH5 and β-catenin expression.</p><p><strong>Conclusion: </strong>This study establishes a link between ALKBH5 and cancer stemness in breast cancer, providing insights into the functional role of demethylase ALKBH5 in breast cancer progression.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"471-482"},"PeriodicalIF":3.3,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD151 Promotes Cancer Progression in Triple-Negative Breast Cancer by Inducing EMT through the MAPK Signaling Pathway.","authors":"Haishu Lv, Beibei Zhang, Xi Weng, Youjia Li, Chaoxian Deng, Rui Wang, Lei Shi, Yuanqin Yin","doi":"10.2147/BCTT.S518760","DOIUrl":"10.2147/BCTT.S518760","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer has become one of the most prevalent malignant neoplasms among women, poses a significant threat to public health. As a member of the tetraspanin family of proteins, CD151 is implicated in tumor progression and has been shown to regulate various cellular and molecular mechanisms that drive malignancy. However, the specific functions of CD151 in triple-negative breast cancer (TNBC) remain unclear. In this study, we aimed to investigate the pro-tumorigenic role of CD151 in TNBC by focusing on its interaction with integrin α3β1, which often forms a complex with CD151.</p><p><strong>Methods: </strong>Our study first evaluated CD151 expression in clinical samples from TNBC patients and TNBC cell lines by immunohistochemistry and Western blotting analysis. Through RNA interference (RNAi) and constructed overexpressed plasmids, we further validated the impact of CD151 on the migration and invasion of TNBC cells. Then the differentially expressed genes were screened by single-cell RNA sequencing, and these genes were enriched and analyzed. Co-immunoprecipitation studies demonstrated the binding of CD151 with integrin α3β1. Western blotting analysis was used to evaluate the expression of proteins related to epithelial-mesenchymal transition (EMT) and Mitogen-activated protein kinase (MAPK) signaling pathway.</p><p><strong>Results: </strong>CD151 is highly expressed in TNBC tissues and cell lines. It enhanced the migration and invasive ability of TNBC cells by promoting EMT. Co-IP demonstrated the binding of CD151 and integrin α3β1. In addition, we found that knockdown of either integrin α3β1 or CD151 reduced the migration and invasion of TNBC cells in vitro. Western blot analysis revealed that the CD151-integrin α3β1 complex could activate the MAPK signaling pathway in TNBC cells, subsequently leading to EMT of these cells.</p><p><strong>Conclusion: </strong>Based on our findings, we propose a novel mechanism by which CD151 mediates tumor progression through the initiation of EMT. This suggests that CD151 could be considered a potential therapeutic target for TNBC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"455-470"},"PeriodicalIF":3.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promising Response to Neoadjuvant Chemotherapy Plus Immunotherapy in Metaplastic Breast Carcinoma.","authors":"Qingjian Tan, Na Li, Yan Wang, Tian Du, Gehao Liang, Zixuan Zhao, Jun Tang, Hao Wu","doi":"10.2147/BCTT.S512790","DOIUrl":"10.2147/BCTT.S512790","url":null,"abstract":"<p><strong>Purpose: </strong>Metaplastic breast carcinoma (MpBC) is a rare and aggressive subtype of breast cancer that often shows poor response to conventional neoadjuvant chemotherapy (NAC). This study aimed to evaluate the efficacy of combining NAC with immune checkpoint inhibitors (ICIs) in MpBC patients.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of MpBC patients treated with NAC, with or without the addition of immunotherapy, at Sun Yat-sen university Cancer center between 2017 and 2024. We assessed clinical and pathological response to NAC in MpBC patients.</p><p><strong>Results: </strong>40 MpBC patients treated with NAC were identified, 33 patients treated with NAC alone, 7 patients treated with NAC and immunotherapy, 4 (10%) patients achieved pCR. Among the 33 patients treated with NAC alone, only 2 (6%) achieved pCR. In contrast, 7 patients received additional immunotherapy, and 3 started immunotherapy at the initiation of NAC, with 2 of these (67%) achieving pCR. Patients who received immunotherapy after disease progression on NAC showed varying degrees of tumor response, from stable disease (SD) to partial response (PR).</p><p><strong>Conclusion: </strong>We observed a promising response on addition of immunotherapy to NAC among patients with MpBC, suggesting that immunotherapy may have great potential in the treatment of metaplastic breast carcinoma.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"447-454"},"PeriodicalIF":3.3,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12109030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to Early Breast Cancer Diagnosis in Sudanese Women Before the War.","authors":"Hana Eltayeb Salih Elamin, Hind Eltayeb Salih Elamin, Ghada Omer Hamad Abd El-Raheem, Mounkaila Noma","doi":"10.2147/BCTT.S506724","DOIUrl":"10.2147/BCTT.S506724","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer in African women is characterized by early onset, late presentation, and consequently poor prognosis. The reason for the late presentation was the delay by patients, due to ignorance, superstition, a skeptical attitude towards western medicine, and dependency on traditional medicine.</p><p><strong>Objective: </strong>The aim of our study was to assess the factors of late presentation at Khartoum Oncology hospital of women suffering from breast cancer.</p><p><strong>Methods: </strong>A hospital based cross-sectional study was implemented to assess the causes related to late presentation of women with breast cancer. Statistical analysis tests done to assess associations among variables were performed through chi². A multi-nominal regression analysis assessed the factors associated to late presentation. All statistical tests were considered significant when <i>p</i><0.05.</p><p><strong>Results: </strong>250 females with breast cancer were studied, their age ranged between 22 years and 77 years with a median of 50 years. Barriers to early presentation were the duration of the condition before presentation (<i>p</i>=0.003) and most importantly the lack of education (<i>p</i>=0.048). As well as having low financial status (<i>p</i>= 0.045) and favouring alternative treatments such as herbal medicine (<i>p</i>=0.041) and Quran therapy (<i>p</i>=0.047). Other reasons were the fear of doctor and surgery (<i>p</i>=0.021) and the fear of diagnosis with a serious condition (<i>p</i>=0.009). Breast cancer was prevalent in all states of Sudan especially Northern state.</p><p><strong>Conclusion: </strong>Fear and seeking treatment alternatives strongly contributed to late presentation. The lack of education and the unawareness about breast self-examination (BSE) are issues needed to be addressed by authorities.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"433-445"},"PeriodicalIF":3.3,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}